Christoph Boss

Allschwil, BL 4123, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Cellular Potency Optimization of Novel Heme-Binding Imidazo[5,1-b]thiazoles, Imidazo[1,5-a]pyridines and Pyrazines as Potent IDO1 Inhibitors Devoid of Cytochrome P450 Inhibition.

Cellular Potency Optimization of Novel Heme-Binding Imidazo[5,1-b]thiazoles, Imidazo[1,5-a]pyridines and Pyrazines as Potent IDO1 Inhibitors Devoid of Cytochrome P450 Inhibition.

Journal: Journal of medicinal chemistry
Published: September 26, 2025

Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists.

Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists.

Journal: ChemMedChem
Published: February 13, 2025

Discovery of ACT-1002-4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti-Tumor Efficacy.

Discovery of ACT-1002-4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti-Tumor Efficacy.

Journal: ChemMedChem
Published: February 13, 2025

Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials.

Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials.

Journal: Journal of medicinal chemistry
Published: February 08, 2024

Design of Dual EP2/EP4 Antagonists through Scaffold Merging of Selective Inhibitors.

Design of Dual EP2/EP4 Antagonists through Scaffold Merging of Selective Inhibitors.

Journal: ChemMedChem
Published: November 01, 2023

Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.

Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.

Journal: RSC medicinal chemistry
Published: October 14, 2023

European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe.

European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe.

Journal: ChemMedChem
Published: March 02, 2023

CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4-Hydroxypiperidinol Metabolites.

CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4-Hydroxypiperidinol Metabolites.

Journal: ChemMedChem
Published: January 20, 2023

Design, Synthesis, and Optimization of Indole Acetic Acid Derivatives as Potent and Selective CRTH2 Receptor Antagonists: Discovery of ACT-774312.

Design, Synthesis, and Optimization of Indole Acetic Acid Derivatives as Potent and Selective CRTH2 Receptor Antagonists: Discovery of ACT-774312.

Journal: ChemMedChem
Published: January 06, 2023

Our Exciting Journey to ACT-451840.

Our Exciting Journey to ACT-451840.

Journal: Chimia
Published: November 20, 2021

20 Years of Medicinal Chemistry - Always Look at the Bright Side (of Life).

20 Years of Medicinal Chemistry - Always Look at the Bright Side (of Life).

Journal: Chimia
Published: August 12, 2020

The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.

The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.

Journal: ChemMedChem
Published: July 15, 2020
Showing 1-12 of 40

Last Updated: 09/26/2026